Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis—what is best in class? Authors’ reply
Date
2018
ISSN
1365-2036Source
Alimentary Pharmacology & TherapeuticsVolume
47Issue
4Pages
540-541Google Scholar check
Metadata
Show full item recordAbstract
Linked Content This article is linked to Bonovas et al and Tsai papers. To view these articles visit https://doi.org/10.1111/apt.14449 and https://doi.org/10.1111/apt.14480.